Tailored eradication strategy vs concomitant therapy for Helicobacter pylori eradication treatment in Korean patients

Table 1 Baseline characteristics of the study population

	TT group (n = 110)	CT group (n = 107)	P value
Age, mean ± SD (yr)	58.66 ± 13.03	56.67 ± 10.88	0.22
Men, n (%)	55 (50.00)	52 (48.60)	0.89
Body mass index (m2/kg)	24.31 ± 3.23	23.87 ± 2.91	0.35
Smoking, n (%)	24 (22.82)	22 (20.59)	0.74
Drinking, n (%)	30 (30.00)	28 (26.17)	0.39
Comorbidity			0.81
Hypertension, n (%)	26 (23.64)	23 (21.50)
Diabetes mellitus, n (%)	22 (20.00)	25 (23.36)
Cardiovascular disease, n (%)	2 (1.82)	2 (1.86)
Reasons for eradication			0.37
Peptic ulcer disease	49 (44.54)	43 (40.19)
Post ESD due to EGC	4 (3.63)	2 (1.87)
MALToma	0 (0.00)	1 (0.93)
Chronic atrophic gastritis with intestinal metaplasia	57 (51.82)	61 (57.01)
Clarithromycin resistance diagnosed by DPO-PCR
No, n (%)	81 (73.64)
A2142G positive, n (%)	4 (3.64)
A2143G positive, n (%)	25 (22.73)
Follow up loss, n (%)	9 (8.18)	10 (9.35)	0.95
Poor compliance, n (%)	0 (0.00)	2 (0.02)	0.30

TT: Tailored therapy; CT: Concomitant therapy; DPO-PCR: Dual priming oligonucleotide polymerase chain reaction; ESD: Endoscopic submucosal dissection; EGC: Early gastric cancer; MALToma: Mucosa associated lymphoid tissue lymphoma.